|
⚲
|
| Keyboard |
| Versant Venture Management LLC
✚
|
|
|---|---|
| CRD # | 161130 |
| SEC # | 802-75823 |
| CIK # | 0001560009 |
| AUM | |
| Employees | |
| Phone | 415-801-8100 |
| Address | One Sansome Street San Francisco, CA 94104 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($) |
|---|
| In the News | |
|---|---|
| Thu, 16 Jul 2026 | Monte Rosa Therapeutics, Inc. $GLUE is Versant Venture Management LLC's Largest Position — MarketBeat |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Monte Rosa Therapeutics Inc | 52.3 | ||
| Century Therapeutics Inc | 27.5 | ||
| Graphite Bio Inc | 24.3 | ||
| Aerovate Therapeutics Inc | 21.4 | ||
| Contineum Therapeutics Inc | 7.1 | ||
| CRISPR Therapeutics AG | 7.1 | ||
| LOAD Guard Logistics Inc | 1.2 | ||
| OvaScience Inc | 0.4 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Versant Venture Capital SPV I SAB LP | 2025-03-27 | 5.9 M | |
| VC | Versant Vantage III Canada LP | 2023-03-29 | 3.5 M | |
| VC | Versant Vantage III LP | [2023-03-29] | 298.7 M | 295.6 M |
| Offered $298,654,822 · Filed 2023-04-07 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Venture Capital IX Canada LP | 2023-03-29 | 7.2 M | |
| VC | Versant Venture Capital IX LP | [2023-03-29] | 600.4 M | 586.2 M |
| Offered $600,357,143 · Filed 2023-04-07 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Voyageurs III Canada LP | 2023-03-29 | 3.7 M | |
| VC | Versant Voyageurs III LP | [2023-03-29] | 300.2 M | 311.8 M |
| Offered $300,178,571 · Filed 2023-04-07 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Vantage II LP | [2021-03-30] | 253.9 M | 249.7 M |
| Offered $253,857,868 · Filed 2021-04-15 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Venture Capital VIII Canada LP | 2021-03-30 | 12.9 M | |
| VC | Versant Venture Capital VIII LP | [2021-03-30] | 560.2 M | 886.9 M |
| Offered $560,244,898 · Filed 2021-04-15 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Voyageurs II Canada LP | 2021-03-30 | 2.3 M | |
| VC | Versant Voyageurs II LP | [2021-03-30] | 140.1 M | 169.0 M |
| Offered $140,061,224 · Filed 2021-04-15 (D/A) · Exemption 506(c), 3(c), 3(c)(7) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Versant Vantage I LP | [2019-03-28] | 69.9 M | |
| Offered $150,000,000 · Filed 2019-03-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $150,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Venture Capital VII LP | [2019-03-28] | 600.0 M | 676.7 M |
| Offered $600,000,000 · Filed 2018-12-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $1,950,000 · Revenue Decline to Disclose | ||||
| VC | Versant Voyageurs I LP | [2019-03-28] | 102.2 M | 87.8 M |
| Offered $102,244,490 · Filed 2019-08-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Voyageurs I Parallel LP | 2019-03-28 | 26.7 M | |
| VC | Versant Venture Capital VI LP | [2017-03-29] | 400.0 M | 275.9 M |
| Offered $400,000,000 · Filed 2017-01-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $375,000 · Revenue Decline to Disclose | ||||
| VC | Versant Venture Capital V Canada LP | 2014-11-24 | 9.2 M | |
| VC | Versant Affiliates Fund V LP | 2014-03-27 | 3.5 M | |
| VC | Versant Ophthalmic Affiliates Fund I LP | 2014-03-27 | 3.9 M | |
| VC | Versant Venture Capital V LP | [2014-03-27] | 295.5 M | 134.9 M |
| Offered $300,000,000 · Filed 2014-06-30 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $4,484,694 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Affiliates Fund I-A LP | [2012-03-30] | 5.2 M | 0.0 M |
| Offered $5,175,000 · Filed 2012-03-23 (D) · Exemption 506, 3(c), 3(c)(1) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Affiliates Fund I-B LP | [2012-03-30] | 11.6 M | 0.1 M |
| Offered $11,625,000 · Filed 2012-03-23 (D) · Exemption 506, 3(c), 3(c)(1), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Affiliates Fund II-A LP | 2012-03-30 | 0.2 M | |
| VC | Versant Side Fund III LP | 2012-03-30 | 0.4 M | |
| VC | Versant Side Fund II LP | [2012-03-30] | 3.6 M | 1.2 M |
| Offered $3,575,000 · Filed 2012-03-23 (D) · Exemption 506, 3(c), 3(c)(1) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Side Fund I LP | [2012-03-30] | 5.0 M | 0.4 M |
| Offered $5,000,000 · Filed 2012-03-23 (D) · Exemption 506, 3(c), 3(c)(1) · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Versant Side Fund IV LP | [2012-03-30] | 0.5 M | |
| VC | Versant Venture Capital III LP | 2012-03-30 | 4.8 M | |
| VC | Versant Venture Capital II LP | 2012-03-30 | 12.3 M | |
| VC | Versant Venture Capital I LP | 2012-03-30 | 0.4 M | |
| VC | Versant Venture Capital IV LP | [2012-03-30] | 38.4 M | |
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Charles Warden | Director | 52 | 3 | |
| Kirk Nielsen | Director | 47 | 3 | |
| Camille Samuels | Director | 17 | 3 | |
| William Link | Director | 81 | 2 | |
| Brian Atwood | Director | 47 | 2 | |
| Bradley Bolzon | Director, Executive Officer | 43 | 2 | |
| Rebecca Robertson | Director | 37 | 2 | |
| Jerel Davis | Director, Executive Officer | 36 | 2 | |
| Ross Jaffe | Director | 31 | 2 | |
| Thomas Woiwode | Director, Executive Officer | 31 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001560009] | |
| 3 | [0001560009] | |
| 4 | [0001560009] |
| Related People Network |
|---|
| 44 people file Form D offerings alongside this firm's people. |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 8,614 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 145,796 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 1,303 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 2,766 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Option exercise | 118,573 | $7.55 | 895,226 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Option exercise | 1,059 | $7.55 | 7,995 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Option exercise | 2,249 | $7.55 | 16,980 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Tax withheld | 45,010 | $19.88 | 894,799 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Tax withheld | 402 | $19.88 | 7,992 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Tax withheld | 854 | $19.88 | 16,978 |
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 603,612 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 5,179 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 10,996 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 1,044,048 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 9,330 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 19,812 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 453,925 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Common Stock
|
2012-10-16 | Conversion | 4,055 | ||
|
Kythera Biopharmaceuticals Inc KYTH
Series D Preferred Stock · derivative
|
2012-10-16 | Conversion | 145,796 | $0.00 | |
|
Kythera Biopharmaceuticals Inc KYTH
Series D Preferred Stock · derivative
|
2012-10-16 | Conversion | 1,303 | $0.00 | |
| showing 20 of 39 most recent transactions | |||||